Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology firm Onyx Pharmaceuticals (NAS: ONXX) are ascending to the heavens today, higher by as much as 42%, after the company announced favorable news for its relapsed and refractory multiple myeloma drug candidate, Kyprolis (aka carfilzomib).

So what: Despite concerns raised by the Food and Drug Administration regarding Kyprolis' toxicity levels and its potentially negative effects on patients' heart, liver, and lungs, an FDA review panel unanimously recommended the drug today. An FDA panel approval does not guarantee that a drug will be approved, as the FDA is under no obligation to follow the panels' decision, but it does often give a good indication as to which way the FDA will side. If approved, Kyprolis will slide in as a tertiary treatment for multiple myeloma for patients who have tried, or were unable to take, Velcade from Takeda Pharmaceutical, and Revlimid from Celgene (NAS: CELG) .


Now what: I have to admit I'm a bit shocked that the vote from the panel was unanimous, but I did expect that Kyprolis' benefits would outweigh the risks. Back in October I outlined multiple reasons that I felt Onyx was a great play going forward, and pretty much all have come to fruition. Even after today's move higher, the possibility of a buyout is very much on the table if Onyx can get Kyprolis approved by the FDA.

Craving more input? Start by adding Onyx Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

The article Why Onyx Pharmaceuticals Shares Skyrocketed originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Managing your Portfolio

Keeping your portfolio and financial life fit!

View Course »

Add a Comment

*0 / 3000 Character Maximum